Cognition Therapeutics reports a smaller-than-expected Q2 loss, with cash reserves totaling $34.8 million as of June 30, 2026.
Cognition Therapeutics posted a Q2 GAAP loss per share of $0.04, exceeding expectations by $0.02. The narrower loss reflects improved financial performance compared to prior periods.
The company reported cash, cash equivalents, and restricted cash equivalents of $34.8 million as of June 30, 2026. Remaining grant funds from the National Institute of Aging also support ongoing operations.
No immediate market reaction was disclosed in the release.